Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086717 | 0.93 | HDAC8 (0.58) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL3109875 | 0.90 | HDAC6 (0.61) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL6087416 | 0.88 | HDAC8 (0.62) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL5464848 | 0.87 | HDAC6 (0.78) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL8690610 | 0.87 | ALDH1A1 (0.57) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL30444258 | 0.87 | HDAC8 (0.58) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL1607787 | 0.87 | KDM4E (0.57) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL3595480 | 0.86 | LMNA (0.51) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL27475780 | 0.85 | HDAC8 (0.56) | HDAC8HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL6179658 | 0.85 | HDAC1 (0.55) | HDAC8HDAC6HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2669270-B1 | INDOLE-RELATED COMPOUNDS AS URAT1 INHIBITORS | SATO PHARMA (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20140005221-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-2669270-A1 | RING-FUSED COMPOUND | Sato Pharmaceutical Co., Ltd. (JP) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012102405-A1 | RING-FUSED COMPOUND | 佐藤製薬株式会社 (JP) | 2012-08-02 | — | — | WO | disclosed |
| US-5811439-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS | SENGA PHARMACEUTICAL LABORATORY INC. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0780389-A1 | Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them | TOBISHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203490-A1 | RING-FUSED COMPOUND | URB2, RCOR1, RCC2 | HDAC8 2042/4885HDAC6 573/4885HDAC1 1517/4885 |
| US-20140005221-A1 | RING-FUSED COMPOUND | URB2, RCOR1, RCC2 | HDAC8 2042/4885HDAC6 573/4885HDAC1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.